The C-terminal fragment of parathyroid hormone-related peptide promotes bone formation in diabetic mice with low-turnover osteopaenia

British Journal of Pharmacology

Volumn 162, Issue 6, 2011, Pages 1424-1438

  Lozano, D ^a   Fernandez De Castro L ^a   Portal Nunez S ^a   Lopez Herradon A ^a   Dapia S ^b   Gomez Barrena E ^c   Esbrit, P ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b Empresa de Base Tecnológica S L   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

bone formation; C terminal PTHrP; diabetes mellitus; osteoblastic cells; osteopaenia

Indexed keywords

CELL MARKER; GLUCOSE; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN 107 139; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BONE MARROW CELL; BONE REGENERATION; BONE STRUCTURE; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRAIN; CELL STRAIN MC3T3 E1; CONTROLLED STUDY; DIABETES MELLITUS; FRACTURE HEALING; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STREPTOZOCIN DIABETES; STROMA CELL;

ABSORPTIOMETRY, PHOTON; ANIMALS; BONE DISEASES, METABOLIC; BONE MARROW CELLS; BONE REGENERATION; BONE RESORPTION; CELL DIFFERENTIATION; DIABETES MELLITUS, EXPERIMENTAL; MALE; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; STREPTOZOCIN; STROMAL CELLS;

EID: 79951989879     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01155.x     Document Type: Article

References (52)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4rd edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Alonso V, de Gortázar AR, Ardura JA, Andrade-Zapata I, Alvarez-Arroyo MV, Esbrit P, (2008). Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. J Cell Physiol 217: 717-727.
3. Barbara A, Delannoy P, Denis BG, Marie PJ, (2004). Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism 53: 532-537. (Pubitemid 38419200)
4. Bisello A, Horwitz MJ, Stewart AF, (2004). Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology 145: 3551-3553. (Pubitemid 39037533)
5. Botolin S, McCabe LR, (2007). Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 148: 198-205. (Pubitemid 46021451)
6. Botolin S, FaugÃre M-C, Malluche H, Orth M, Meyer R, McCabe LR, (2005). Increased bone adiposity and peroxisomal proliferators-activated receptor-γ2 expression in type I diabetic mice. Endocrinology 146: 3622-3631. (Pubitemid 41058134)
7. Carpio L, Gladu J, Goltzman D, Rabbani SA, (2001). Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Physiol Endocrinol Metab 281: E489-E499.
8. de Castro LF, Lozano D, Dapía S, Portal-Nuñez S, Caeiro JR, Gomez-Barrena E, et al. (2010). Role of the N- and C-terminal fragments of parathyroid hormone-related protein as putative therapies to improve bone regeneration under high glucocorticoid treatment. Tissue Eng Part A 16: 1157-1168.
9. Chen C, Koh AJ, Datta NS, Zhang J, Keller ET, Xiao G, et al. (2004). Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. J Biol Chem 279: 29121-29129. (Pubitemid 38915784)
10. Chen H-L, Demiralp B, Schneider A, Koh AJ, Silve C, Wang C-Y, et al. (2002). Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 277: 19374-19381. (Pubitemid 34967444)
11. Connor JR, Dodds RA, James IE, Gowen M, (1995). Human osteoclast and giant cell differentiation: the apparent switch from nonspecific esterase to tartrate resistant acid phosphatase activity coincides with the in situ expression of osteopontin mRNA. J Histochem Cytochem 43: 1193-1201.
12. Cornish J, Callon KE, Nicholson GC, Reid IR, (1997). Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo. Endocrinology 138: 1299-1304. (Pubitemid 27089790)
13. Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR, (1999). Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 14: 915-922. (Pubitemid 29262885)
14. Cuthbertson RM, Kemp BE, Barden JA, (1999). Structure study of osteostatin PTHrP[Thr107](107-139). Biochim Biophys Acta 1432: 64-72. (Pubitemid 29299232)
15. Dean T, Vilardaga JP, Potts JT Jr, Gardella TJ, (2008). Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol 22: 156-166.
16. Esbrit P, Alvarez-Arroyo MV, De Miguel F, Martín O, Martínez ME, Caramelo C, (2000). C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 11: 1085-1092. (Pubitemid 30367938)
17. Fenton AJ, Kemp BE, Hammonds RG, Mitchelhill K, Moseley JM, Martin TJ, et al. (1991a). A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of PTHrP (107-111). Endocrinology 129: 3424-3426.
18. Fenton AJ, Kemp BE, Kent GN, Moseley JM, Zheng MH, Rowe DJ, et al. (1991b). A carboxyl-terminal peptide from the parathyroid hormone-related protein inhibits bone resorption by osteoclasts. Endocrinology 129: 1762-1768.
19. Goltzman D, (2008). Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 473: 218-224.
20. de Gortázar AR, Alonso V, Alvarez-Arroyo MV, Esbrit P, (2006). Transient exposure to PTHrP-107-139 exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 79: 360-369. (Pubitemid 44900159)
21. Guillén C, Martínez P, de Gortázar AR, Martínez ME, Esbrit P, (2002). Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by NF-κB activation in osteoblastic cells. J Biol Chem 277: 28109-28117. (Pubitemid 34966763)
22. Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M, (2007). Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 40: 1408-1414. (Pubitemid 46550975)
23. Hayman AR, Macary P, Lehner PJ, Cox TM, (2001). Tartrate-resistant acid phosphatase (Acp 5): identification in diverse human tissues and dendritic cells. J Histochem Cytochem 49: 675-683. (Pubitemid 32553438)
24. Hildreth BE, Hildreth BE 3rd, Werbeck JL, Thudi NK, Deng X, Rosol TJ, et al. (2010). PTHrP 1-141 and 1-86 increase in vitro bone formation. J Surg Res 16: e9-e17.
25. Hofbauer L, Brueck CC, Singh SK, Dobnig H, (2007). Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22: 1317-1328. (Pubitemid 351339677)
26. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocaña A, Stewart AF, (2003). Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 569-575. (Pubitemid 36207792)
27. Inzerillo A, Epstein S, (2004). Osteoporosis and diabetes mellitus. Rev Endocrine Metab Dis 5: 261-268. (Pubitemid 38903584)
28. Izquierdo A, López-Luna P, Ortega A, Romero M, Gutiérrez-Tarrés MA, Arribas I, et al. (2006). The parathyroid hormone-related protein system and diabetic nephropathy outcome in streptozotocin-induced diabetes. Kidney Int 12: 2171-2177.
29. Jacobsen KA, Al-Aql ZS, Wan C, Fitch JL, Stapleton SN, Mason ZD, et al. (2008). Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 23: 596-609. (Pubitemid 351575014)
30. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS, (2006). Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147: 5592-5599. (Pubitemid 44833476)
31. Kawashima Y, Fritton JC, Yakar S, Epstein S, Schaffler MB, Jepsen KJ, et al. (2009). Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone 44: 648-655.
32. Kim YH, Jun JH, Woo KM, Ryoo HM, Kim GS, Baek JH, (2006). Dexamethasone inhibits the formation of multinucleated osteoclasts via down-regulation of beta3 integrin expression. Arch Pharm Res 29: 691-698.
33. Legakis I, Mantouridis T, (2009). Positive correlation of PTH-related peptide with glucose in type 2 diabetes. Exp Diabetes Res 2009: 291027.
34. Lozano D, de Castro LF, Dapía S, Andrade-Zapata I, Manzarbeitia F, Alvarez-Arroyo MV, et al. (2009). Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 150: 2027-2035.
35. Lozano D, Manzano M, Doadrio JC, Salinas AJ, Vallet-Regí M, Gómez-Barrena E, et al. (2010). Osteostatin-loaded bioceramics stimulate osteoblastic growth and differentiation. Acta Biomater 6: 797-803.
36. Lu H, Kraut D, Gerstenfeld LC, Graves DT, (2003). Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 144: 346-352. (Pubitemid 36076124)
37. McCabe LR, (2007). Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 102: 1343-1357. (Pubitemid 350223938)
38. Martin TJ, (2005). Osteoblast-derived PTHrP is a physiological regulator of bone formation. J Clin Invest 115: 2322-2324. (Pubitemid 41266192)
39. Miao D, Su H, He B, Gao J, Xia Q, Zhu M, et al. (2008). Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc Natl Acad Sci U S A 105: 20309-20311.
40. de Miguel F, Fiaschi-Taesch N, López-Talavera JC, Takane KK, Massfelder T, Helwig JJ, et al. (2001). The C-terminal region of PTHrP, in addition to the nuclear localization signal, is essential for the intracrine stimulation of proliferation in vascular smooth muscle cells. Endocrinology 142: 4096-4105. (Pubitemid 32802683)
41. Murrills RJ, Stein LS, Dempster DW, (1995). Lack of significant effect of carboxyl-terminal parathyroid hormone-related peptide fragments on isolated rat and chick osteoclasts. Calcif Tissue Int 57: 47-51.
42. Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, et al. (2009). Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 84: 4534-4561.
43. Nuche-Berenguer B, Moreno P, Portal-Nuñez S, Dapía S, Esbrit P, Villanueva-Peñacarrillo ML, (2010). Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 159: 61-66.
44. Okuda N, Takeda S, Shinomiya K, Muneta T, Itoh S, Noda M, et al. (2007). ED-71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablation. Bone 40: 281-292. (Pubitemid 46075203)
45. Rouffet J, Coxam V, Gaumet N, Barlet JP, (1994). Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments. Reprod Nutr Dev 34: 473-481. (Pubitemid 24351291)
46. Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, Nyman JS, et al. (2009). Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. J Bone Miner Res 24: 1618-1627.
47. Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM, (2000). Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15: 1517-1525. (Pubitemid 30484521)
48. Suzuki K, Sugimoto C, Takizawa M, Ishizuka S, Kikuyama M, Togawa H, et al. (2000). Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res Clin Pract 48: 185-191. (Pubitemid 30232839)
49. Toribio RE, Brown HA, Novince CM, Marlow B, Hernon K, Lanigan LG, et al. (2010). The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J 24: 1947-1957.
50. Valín A, García-Ocaña A, De Miguel F, Sarasa JL, Esbrit P, (1997). Antiproliferative effect of the C-terminal fragments of parathyroid hormone-related protein, PTHrP-(107-111) and (107-139), on osteoblastic osteosarcoma cells. J Cell Physiol 170: 209-215. (Pubitemid 27076222)
51. 2+ through a receptor different from the type 1 PTH/PTHrP receptor in osteoblastic osteosarcoma UMR 106 cells. Endocrinology 142: 2752-2759. (Pubitemid 32575509)
52. Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, et al. (2008). High D(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 42: 1122-1130.